ArticleOPEN ACCESS

The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

Intensive Care Medicine
DOI: 10.1007/s00134-021-06540-w
9Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Cite

CITATION STYLE

APA

Tatham, K. C., Shankar-Hari, M., & Arabi, Y. M. (2021, November 1). The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? Intensive Care Medicine. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s00134-021-06540-w

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free